Radiotherapeutics were a major topic at ASCO this year, as more and more studies progress on a variety of targets, isotopes, ...

Takeda presented data across a range of therapeutics and indications at ASCO 2026, including on investigational drugs like ...

Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. The funding aims to improve clinical trials, manufacturing, and HTA across the four nations of the UK. The scheme ...

Armed with new clinical data, Novartis is planning to talk to global regulators about possible filings for delpacibart braxlosiran (del-brax), which could become the first disease-modifying treatment ...

Our latest roundup of venture capital financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics. San Francisco-based SonoThera closed an ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

Bayer's oral Factor XIa inhibitor asundexian is now under regulatory review by the EMA for secondary prevention of ischaemic ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...